Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Ann Thorac Surg1
Search Results
Sort by
- BookMieczyslaw Pokorski, editor.Summary: Lung cancer and autoimmune diseases are complex entities in that they involve gene disturbance, gene polymorphism, and impaired gene repair mechanisms. The volume focuses on altered gene expression in tumor processes and in chronic autoimmune disorders. The chapters discuss the biological rationale for novel disease protein markers, present relevant clinical results, and give some diagnostic and therapeutic tips.Digital Access Springer 2015Access via Advances in experimental medicine and biology ; 2015; 833LocationVersionCall NumberItems
- ArticleBoudoulas H, Snyder GL, Lewis RP, Kates RE, Karayannacos PE, Vasko JS.Ann Thorac Surg. 1978 Sep;26(3):222-7.Thirty consecutive patients undergoing coronary bypass were studied. Oral propranolol therapy was maintained up to 4 to 10 hours before operation. Nineteen of the patients had a history of myocardial infarction (MI), 14 had hypoakinetic areas, and 8 had decreased ejection fraction indicating advanced coronary artery disease. Twenty-four-hour urinary epinephrine and norepinephrine obtained the day before operation were markedly increased at 136 +/- 12 microgram per 24 hours (normal, 39 +/- 4 microgram, rho less than 0.01). There were 4 perioperative MIs (13%) and no deaths. Plasma propranolol 1 hour before operation was 43.3 +/- 8 ng per milliliter, indicating good beta blockade. Propranolol was started within 24 hours postoperatively. There were no preoperative, intraoperative, or postoperative complications related to propranolol therapy. We conclude that because of markedly increased adrenergic tone the day before operation and transient hypersensitivity to adrenergic stimulation after withdrawal of propranolol, this agent should be continued through coronary bypass operation.